Aurinia Pharmaceuticals (AUPH) Income towards Parent Company (2018 - 2025)
Historic Income towards Parent Company for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $31.6 million.
- Aurinia Pharmaceuticals' Income towards Parent Company rose 12052.84% to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.9 million, marking a year-over-year increase of 44339.07%. This contributed to the annual value of $5.7 million for FY2024, which is 10736.27% up from last year.
- As of Q3 2025, Aurinia Pharmaceuticals' Income towards Parent Company stood at $31.6 million, which was up 12052.84% from $21.5 million recorded in Q2 2025.
- In the past 5 years, Aurinia Pharmaceuticals' Income towards Parent Company registered a high of $31.6 million during Q3 2025, and its lowest value of -$50.4 million during Q1 2021.
- For the 5-year period, Aurinia Pharmaceuticals' Income towards Parent Company averaged around -$15.0 million, with its median value being -$13.4 million (2023).
- Per our database at Business Quant, Aurinia Pharmaceuticals' Income towards Parent Company tumbled by 10633.75% in 2021 and then surged by 307300.88% in 2025.
- Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Income towards Parent Company stood at -$33.3 million in 2021, then increased by 21.84% to -$26.0 million in 2022, then fell by 3.34% to -$26.9 million in 2023, then soared by 105.47% to $1.5 million in 2024, then skyrocketed by 2041.96% to $31.6 million in 2025.
- Its Income towards Parent Company was $31.6 million in Q3 2025, compared to $21.5 million in Q2 2025 and $23.3 million in Q1 2025.